Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index
Wen Shen(Ionis Pharmaceuticals (United States)), Cheryl Li De Hoyos(Ionis Pharmaceuticals (United States)), Michael T. Migawa(Ionis Pharmaceuticals (United States)), Timothy A. Vickers(Ionis Pharmaceuticals (United States)), Hong Sun(Ionis Pharmaceuticals (United States)), Audrey Low(Ionis Pharmaceuticals (United States)), Thomas A. Bell(Ionis Pharmaceuticals (United States)), Meghdad Rahdar(Ionis Pharmaceuticals (United States)), Swagatam Mukhopadhyay(Ionis Pharmaceuticals (United States)), Christopher E. Hart(Ionis Pharmaceuticals (United States)), Melanie Bell(Ionis Pharmaceuticals (United States)), Stan Riney(Ionis Pharmaceuticals (United States)), Susan Murray(Ionis Pharmaceuticals (United States)), Sarah Greenlee(Ionis Pharmaceuticals (United States)), Rosanne M. Crooke(Ionis Pharmaceuticals (United States)), Xue‐hai Liang(Ionis Pharmaceuticals (United States)), Punit P. Seth(Ionis Pharmaceuticals (United States)), Stanley T. Crooke(Ionis Pharmaceuticals (United States))
Cited by 328
Abstract
Related Papers
No related papers found
Powered by citation graph analysis